TARS News & Analysis
3 articles
Market Mood
TARSUS Stock Target Set at $88 by H.C. Wainwright
H.C. Wainwright has reiterated a Buy rating on Tarsus (TARS) stock with a target price of $88 following its recent acquisition announcement. This recommendation comes as a part of their analysis on the company's future growth prospects post-acquisition. The reiteration of the Buy rating suggests confidence in Tarsus's ability to leverage the acquisition for enhanced market performance. For investors, this could signal a potential opportunity in Tarsus stock, as the target price indicates substantial upside potential.
Read More: TARSUS Stock Target Set at $88 by H.C. Wainwright
Tarsus Pharmaceuticals (TARS) Form 144 Filed on June 15
Tarsus Pharmaceuticals (TARS) filed Form 144 on June 15, indicating a potential sale of shares by insiders. Form 144 is typically used to notify the SEC about the intention to sell restricted or control securities. This event may influence market perceptions regarding the liquidity and activity of insider trades. Investors often monitor such filings for insights into management confidence and stock performance, making this filing notable in the context of TARS's stock liquidity.
Read More: Tarsus Pharmaceuticals (TARS) Form 144 Filed on June 15
TARS (TARS) DEF 14A Filing Completed April 28
Tarsus Pharmaceuticals (TARS) submitted its DEF 14A filing on April 28. This form typically outlines important information for shareholders, including governance issues and executive compensation. Such filings are essential for transparency and can influence investor sentiment and company valuations. As of the latest data, TARS aims to provide detailed disclosures to its shareholders, which can positively affect market confidence.
Read More: TARS (TARS) DEF 14A Filing Completed April 28